Skip to navigation Skip to main content
Renal and Urology News
  • Prostate Cancer
  • ED
  • CKD
  • Urology
    • Urology
      • Urology News
      • Conference Coverage
      • Benign Prostatic Hyperplasia (BPH)
      • Bladder Cancer
      • Erectile Dysfunction
      • Hypogonadism
      • Kidney Cancer
      • Kidney Stones
      • Men’s Health
      • Overactive Bladder (OAB)
      • Premature Ejaculation
      • Prostate Cancer
      • Reproductive Medicine
      • Upper Tract Urothelial Carcinoma
      • Urinary Incontinence
      • Urinary Tract Infections (UTI)
  • Nephrology
    • Nephrology
      • Nephrology
      • Conference Coverage
      • Acute Kidney Injury
      • Anemia
      • Contrast Nephropathy
      • Cardiovascular Disease (CVD)
      • Chronic Kidney Disease (CKD)
      • Diabetes
      • Diabetic Nephropathy
      • End-Stage Renal Disease
      • Hemodialysis
      • Hyperkalemia
      • Hyperphosphatemia
      • Hypertension
      • Hyperuricemia
      • Lupus Nephritis
      • Nutrition
      • Peritoneal Dialysis
      • Secondary Hyperparathyroidism
      • Transplantation
  • My Practice
    • My Practice
      • Commentary
      • Drug Information Database
      • Ethical Issues in Medicine
      • General Medicine
      • HIPAA Compliance
      • Legal Issues in Medicine
      • Practice Management
      • Product Guide
      • Renal Nutrition Update
  • Web Exclusives
    • Web Exclusives
      • Expert Perspectives
      • Cartoons
      • Clinical Quiz
      • Drugs in the Pipeline
      • Medical Calculators
      • Clinical Charts
      • Multimedia
      • Polls
      • Prostate Cancer Management Across America
  • Conferences
  • Resources
  • Headlines
  • Jobs
  • Commentary
  • Poll
  • Drugs
  • CME
  • Submit

Oncology » Bladder, kidney, and other urologic cancers

Bladder, kidney, and other urologic cancers

Drug Name

  • AFINITOR
  • ALYMSYS
  • AVASTIN
  • BALVERSA
  • BAVENCIO
  • Bladder Cancer Risk Elevated in Statin Users
  • CABOMETYX
  • Cisplatin
  • COSMEGEN
  • DEPO-PROVERA
  • Doxorubicin HCl
  • Doxorubicin HCl Solution
  • FDA Approves New First-Line Treatment for Advanced RCC
  • FOTIVDA
  • Higher Vitamin D Levels Reduce the Likelihood of Kidney Cancer
  • IMFINZI
  • INLYTA
  • JELMYTO
  • KEYTRUDA
  • Kidney Cancer Linked to Adolescent Overweight, Obesity
  • LENVIMA
  • MVASI
  • NEXAVAR
  • OPDIVO
  • PADCEV
  • PROLEUKIN
  • RCC Tumor Size Affects PN, Cryoablation Survival Outcomes
  • Robotic Partial Nephrectomy May Be a Viable Option for Large Renal Tumors
  • Standard of Care for mRCC May Change
  • SUTENT
  • Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients
  • TECENTRIQ
  • TEPADINA
  • Thiotepa
  • TICE BCG
  • TORISEL
  • TRODELVY
  • VALSTAR
  • Vincristine Sulfate PFS
  • VOTRIENT
  • WELIREG
  • YERVOY
  • ZIRABEV
  • Loading...

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Back to Top
  • Renal & Urology News publishes timely news coverage of scientific developments of interest to nephrologists and urologists, including in-depth coverage of all relevant medical conferences.

    All of the news and departments from the print edition are fully archived on the site.

  • Resources
    • Editorial Board
    • Reprints/Permissions
    • Issue Archive
  • User Center
    • About Us
    • Contact Us
    • Advertise
    • Ad Choices
  • Other Haymarket Medical Websites
    • Cancer Therapy Advisor
    • Clinical Advisor
    • Clinical Pain Advisor
    • Dermatology Advisor
    • Endocrinology Advisor
    • Gastroenterology Advisor
    • Hematology Advisor
    • Infectious Disease Advisor
    • McKnight’s Long Term Care News
    • McKnight’s Senior Living
    • Medical Bag
    • MPR
    • myCME
    • Neurology Advisor
    • Oncology Nurse Advisor
    • Ophthalmology Advisor
    • Optometry Advisor
    • Psychiatry Advisor
    • Pulmonology Advisor
    • Rare Disease Advisor
    • Rheumatology Advisor
    • The Cardiology Advisor
  • Copyright © 2023 Haymarket Media, Inc. All Rights Reserved
    This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
    Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.

Loading...
Loading...